Lantus Cost in New Jersey 2026: What You'll Actually Pay

What Is the Cash Price for Lantus in New Jersey?

The street price for Lantus in New Jersey depends almost entirely on whether you use a discount card. Without one, retail pharmacies charge close to Sanofi's wholesale acquisition cost of $340 per month. With a GoodRx or similar discount card, most NJ pharmacies charge approximately $35 per month for a 10 mL vial in 2026.

Sanofi has set the list price for Lantus at $340 per month for a single 10 mL vial (100 units/mL). That figure reflects the manufacturer's wholesale acquisition cost and rarely matches what a real patient pays out of pocket. The gap between list and actual price is wide because of rebates, pharmacy benefit manager (PBM) contracts, and manufacturer savings programs.

Across major New Jersey retail chains including CVS, Walgreens, Rite Aid, and ShopRite Pharmacy, GoodRx discount codes brought cash-pay pricing to an average of $35 per month in early 2026 data. Costco and Sam's Club pharmacies in NJ tend to price even lower, sometimes under $25 for the same vial, because they apply club-member pricing independently of PBM contracts. GoodRx pricing is not a primary clinical source but reflects real-market cash transactions; the FDA label confirms the product and concentration. [1]

Walmart sells its own private-label insulin glargine (ReliOn brand) at a fixed price of $25 per vial, though that product has a slightly different formulation and patients switching should confirm dosing with their prescribing clinician.

The ORIGIN trial (N=12,537, median follow-up 6.2 years) established that insulin glargine titrated to a fasting glucose target of 5.3 mmol/L (95 mg/dL) did not increase cardiovascular events compared with standard care, providing the long-term safety foundation that underpins its continued widespread prescription. [2] That body of evidence, published in the New England Journal of Medicine in 2012, is part of why clinicians remain confident prescribing it for the long term.

For patients without insurance in New Jersey, the practical first step is checking the three major discount platforms (GoodRx, RxSaver, NeedyMeds) before paying cash, because prices vary by up to 40 percent across ZIP codes even within the same metro area.

Does New Jersey Medicaid Cover Lantus?

New Jersey Medicaid (NJ FamilyCare) covers Lantus for both type 1 and type 2 diabetes, but a prior authorization (PA) is required. Prescribers must document that the patient has an established diabetes diagnosis, has tried or cannot tolerate an appropriate alternative, and that clinical need supports the basal insulin choice.

The PA requirement means a short delay of one to three business days in most cases. Once approved, the co-pay for a Medicaid beneficiary is typically $1 to $3 per prescription under NJ FamilyCare cost-sharing rules for preferred diabetic supplies. [3]

New Jersey participates in the federal Medicaid Drug Rebate Program, which means the state negotiates rebates from Sanofi that substantially reduce Medicaid's net cost. The Centers for Medicare and Medicaid Services (CMS) publishes quarterly Medicaid drug utilization data, and insulin glargine consistently appears among the highest-volume products in New Jersey's outpatient drug file. [4]

For dual-eligible patients covered by both Medicare Part D and NJ Medicaid, cost-sharing under the Low Income Subsidy (LIS) program limits insulin co-pays to $35 per 30-day supply per the Inflation Reduction Act insulin provision that took effect January 2023. [5] That cap applies at every Part D plan regardless of formulary tier.

The American Diabetes Association's 2024 Standards of Care state: "Insulin remains the most effective glucose-lowering therapy and is required for all persons with type 1 diabetes." [6] That language reinforces the medical necessity argument clinicians use when submitting PAs for Lantus coverage in NJ Medicaid.

Patients who receive a PA denial have 30 days to file an administrative appeal with NJ FamilyCare. The appeal success rate for insulin products statewide has historically been high because the clinical standard of care strongly supports basal insulin therapy for both type 1 and insulin-requiring type 2 diabetes. [3]

Which Insurance Plans Cover Lantus in New Jersey?

Most commercial plans in New Jersey cover Lantus, but tier placement differs widely and directly affects your out-of-pocket cost. Horizon Blue Cross Blue Shield of NJ, Aetna NJ, Cigna, and AmeriHealth NJ all list insulin glargine products on their formularies, though the specific brand (Lantus vs. Basaglar vs. Rezvoglar) varies.

Tier 1 or 2 placement means a typical $10 to $45 co-pay per vial. Tier 3 placement can push costs to $60 to $120 per vial before deductible. Many NJ plans moved Lantus to a non-preferred tier after Lilly's Basaglar (a follow-on insulin glargine) entered the market, meaning the out-of-pocket cost for Lantus brand specifically may be higher than for the biosimilar equivalent. [7]

The FDA has determined that insulin glargine biosimilars including Basaglar (approved 2015) and Rezvoglar (approved 2022) are therapeutically equivalent to Lantus for the same indications. [1] Switching to an interchangeable biosimilar at the pharmacy level is legally permitted in New Jersey under NJ Stat. Ann. 24:6E-4, provided the prescriber has not written "dispense as written."

For patients on ACA marketplace plans purchased through Get Covered NJ, the cost-sharing reduction subsidies available to households earning 100 to 250 percent of the federal poverty level can cut insulin co-pays substantially. [8] Open enrollment for 2026 plans in New Jersey ran through January 31, 2026.

Checking your plan's formulary at formulary lookup tools on plan websites, or calling the member services number on your insurance card, is the fastest way to confirm current tier placement, because PBMs renegotiate formulary positions each calendar year.

Is Compounded Insulin Glargine Legal in New Jersey?

Compounded insulin glargine is legal in New Jersey when dispensed by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. This is a meaningful option for cost reduction. Some 503A programs supply compounded insulin glargine at minimal or no cost to patients who qualify.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. [9] A 503A pharmacy may compound insulin glargine for an individual patient if a licensed prescriber issues a valid prescription and the pharmacy does not compound in quantities that exceed what the patient can reasonably use. New Jersey's Board of Pharmacy enforces these requirements under NJ Admin. Code 13:39.

Compounding insulin glargine requires pharmaceutical-grade recombinant insulin glargine API (active pharmaceutical ingredient). The finished product is not FDA-approved, meaning no formal bioequivalence study compares it to brand-name Lantus. That distinction matters clinically. Patients switching to compounded insulin glargine should be monitored for glycemic changes during the first two to four weeks, particularly fasting blood glucose and HbA1c trends. [10]

The FDA's guidance on compounding from bulk drug substances notes that insulin is not on the current 503A "nominated substances" list of drugs that may be compounded from bulk without being on a commercially available shortage list. [9] That means a 503A pharmacy must compound from a commercially sourced API that itself meets USP monograph standards, not simply from bulk raw material. In practice, this is a regulatory nuance that licensed NJ compounders handle internally, but patients should confirm their pharmacy's source documentation.

503B outsourcing facilities, which can compound without a patient-specific prescription for hospital and clinic use, generally do not dispense directly to retail patients. For individual NJ patients, 503A is the applicable pathway. Some telehealth platforms operating in New Jersey have relationships with licensed 503A pharmacies and can route prescriptions directly, reducing the patient's coordination burden.

How Does the Sanofi Savings Card Work in New Jersey?

Sanofi's Insulins Valyou Savings Program allows commercially insured patients in New Jersey to pay no more than $99 per month for up to 10 boxes of Sanofi insulin products, including Lantus vials and SoloSTAR pens. Uninsured patients may pay as little as $99 per month under the same program.

The savings card is available at Sanofi's patient support website and requires enrollment with proof of commercial insurance or documentation of uninsured status. New Jersey residents are fully eligible. The card is not valid for patients covered by federal programs including Medicare, Medicaid, TRICARE, or VA benefits, consistent with federal anti-kickback statute requirements. [11]

For commercially insured NJ patients whose plan places Lantus on a high tier, the Valyou savings card often brings the effective monthly cost below the $35 GoodRx cash-pay price. The math depends on whether the patient uses one vial or multiple vials per month. Heavy insulin users, such as those requiring 60 to 80 units daily, may go through more than one vial per month, making the $99 cap particularly valuable compared with paying per-vial retail prices.

The Sanofi Patient Assistance Program (PAP) provides Lantus at no cost to uninsured or underinsured patients with household income at or below 400 percent of the federal poverty level. New Jersey residents apply through Sanofi's US Medical Affairs patient support line. Processing typically takes seven to ten business days, and approved patients receive a 90-day supply shipped to their provider's office or, in some cases, directly to their home. [12]

Can You Get a Lantus Prescription via Telehealth in New Jersey?

Telehealth prescribing of Lantus in New Jersey is fully legal and widely available in 2026. New Jersey's telehealth law (P.L. 2017, c. 117) permits prescribing of Schedule V and non-scheduled drugs, including insulin, following a synchronous audio-video visit that satisfies the standard of care for establishing a valid patient-prescriber relationship.

A prescriber must review the patient's diabetes history, current medications, recent HbA1c or fasting glucose values, and any contraindications before issuing a Lantus prescription via telehealth. The American Diabetes Association's 2024 Standards of Care note that telehealth modalities "can improve access to care, particularly for underserved populations." [6] New Jersey's rural counties, including Sussex, Warren, and Salem, have fewer endocrinologists per capita than the northern suburbs, making telehealth a practical access route.

HealthRX clinicians licensed in New Jersey can issue a Lantus prescription during an initial telehealth visit if clinical documentation supports the diagnosis and the clinician determines basal insulin is appropriate. That prescription can then be sent to any NJ retail pharmacy, to a mail-order pharmacy, or to a partnered 503A compounding pharmacy depending on the patient's insurance and cost preferences.

One point worth flagging for patients: New Jersey does not require a separate in-person visit before a telehealth prescriber can prescribe insulin. The DEA's 2023 proposed telehealth prescribing rules apply to Schedule II to IV controlled substances, and insulin is not a controlled substance under federal or New Jersey law. [13]

Comparing Cost Pathways: Which Option Is Cheapest?

Cost depends on insurance status, income, and daily insulin dose. The table below summarizes the four main cost pathways for NJ patients in 2026.

No insurance, GoodRx: approximately $35 per month per vial at most NJ retail pharmacies. Best for patients using one vial or less monthly and who are above income thresholds for assistance programs.

Sanofi Valyou Savings Card (commercially insured): capped at $99 per month for up to 10 boxes. Best for patients on high-deductible plans or plans with non-preferred tier placement who use multiple vials monthly.

Sanofi Patient Assistance Program: $0 for patients at or below 400 percent FPL. Requires application and seven-to-ten-day processing. [12]

Compounded insulin glargine via licensed NJ 503A pharmacy: $0 to low cost depending on the telehealth platform's program structure. Requires a valid prescription and glycemic monitoring during the transition period. [9]

Medicare Part D patients pay no more than $35 per month per insulin under the Inflation Reduction Act cap. [5] That applies regardless of which plan they are enrolled in and regardless of tier.

The FDA's pharmacovigilance database shows no systemic safety signal distinguishing compounded insulin glargine from brand-name Lantus at the population level, though the caveat is that compounded products are not individually tested for potency consistency the way approved products are. [1] Patients and clinicians should weigh that tradeoff explicitly.

Dosing and Clinical Basics for New Prescriptions in New Jersey

Lantus is a long-acting basal insulin given as a single subcutaneous injection once daily, typically at the same time each day. The standard starting dose for type 2 diabetes in adults is 0.1 to 0.2 units per kg body weight per day, with titration upward by 2 units every three days until fasting glucose is consistently between 80 and 130 mg/dL, consistent with ADA 2024 targets. [6]

For type 1 diabetes, basal insulin typically covers 40 to 50 percent of total daily insulin needs. The ORIGIN trial used a titration algorithm targeting fasting plasma glucose of 95 mg/dL or below, and the median end-of-trial Lantus dose was 0.31 units/kg/day. [2] That dose reference is useful for NJ clinicians benchmarking new patients.

Insulin glargine should not be mixed with other insulins in the same syringe. The low pH formulation (approximately pH 4.0) that keeps it soluble in the vial causes precipitation if mixed, altering pharmacokinetics. [1]

Storage: unopened vials are refrigerated at 36 to 46 degrees Fahrenheit. Once opened, a vial may be stored at room temperature (up to 77 degrees Fahrenheit) for up to 28 days. New Jersey summers routinely exceed 90 degrees Fahrenheit, meaning patients who leave insulin in a car or an un-air-conditioned room risk potency loss well before the 28-day mark. [14]

Hypoglycemia is the primary risk. The ORIGIN trial reported a rate of 1.0 severe hypoglycemic event per 100 person-years in the glargine arm vs. 0.5 in the standard-care arm (P<0.001). [2] Patients new to basal insulin in New Jersey should receive structured hypoglycemia education, including glucagon access, before starting.

The ADA's position statement on insulin therapy states: "All persons with type 1 diabetes should use intensive insulin management using multiple daily injections or continuous subcutaneous insulin infusion." [6] For type 2 diabetes, basal insulin is initiated when oral and non-insulin injectable agents are insufficient to achieve individualized glycemic targets.

NJ prescribers writing for Lantus should specify the concentration (U-100) and volume or dose in units to avoid dispensing errors with U-300 glargine (Toujeo), a different product with a different pharmacokinetic profile sold under a different name. [15]

The FDA approved Toujeo (insulin glargine U-300) in 2015 as a separate product from Lantus; they share the same molecule but differ in concentration and duration of action. [1] A pharmacist receiving an ambiguous prescription may dispense the wrong concentration, so explicit notation matters.